Literature DB >> 10764161

The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation.

M Vickers1, G Jackson, P Taylor.   

Abstract

It is believed that most malignancies become more common with increasing age due to the requirement for several mutations to accumulate and subsequently interact. The age specific incidence of acute promyelocytic leukemia (APL) was investigated using population-based data from 77 million subject years of observation, yielding 149 consecutive cases. The incidence appears approximately constant with respect to age, an observation not previously reported with any other malignancy. These findings are most easily explained by there being only one rate limiting genetic event required to initiate the disease, although other, non-rate limiting mutations may also be necessary for disease development. It is also argued that this mutation is probably restricted to cells committed to differentiation, which may explain why APL is curable by chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764161     DOI: 10.1038/sj.leu.2401722

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  22 in total

1.  Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.

Authors:  Alireza Eghtedar; Ildefonso Rodriguez; Hagop Kantarjian; Susan O'Brien; Naval Daver; Guillermo Garcia-Manero; Alessandra Ferrajoli; Tapan Kadia; Sherry Pierce; Jorge Cortes; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2014-11-03

Review 2.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

3.  LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.

Authors:  X Wang; Q Lin; F Lv; N Liu; Y Xu; M Liu; Y Chen; Z Yi
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

4.  Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.

Authors:  Graça M Dores; Susan S Devesa; Rochelle E Curtis; Martha S Linet; Lindsay M Morton
Journal:  Blood       Date:  2011-11-15       Impact factor: 22.113

Review 5.  Acute myelogenous leukemia in adolescents and young adults.

Authors:  Ursula Creutzig; Matthew A Kutny; Ronald Barr; Richard F Schlenk; Raul C Ribeiro
Journal:  Pediatr Blood Cancer       Date:  2018-04-18       Impact factor: 3.167

Review 6.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

7.  Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models.

Authors:  Raajit K Rampal; Ross L Levine
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

Review 8.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

9.  RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.

Authors:  Nathalie Girard; Mathieu Tremblay; Magali Humbert; Benoît Grondin; André Haman; Jean Labrecque; Bing Chen; Zhu Chen; Sai-Juan Chen; Trang Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

Review 10.  Differentiation therapy revisited.

Authors:  Hugues de Thé
Journal:  Nat Rev Cancer       Date:  2017-12-01       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.